Jon Stoessl

List of Publications by Citations

261 papers	18,979 citations	62 h-index	133 g-index
290 ext. papers	21,397 ext. citations	7.9 avg, IF	6.3 L-index

#	Paper	IF	Citations
261	Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron*, **2004**, 44, 601-7	13.9	2228
260	A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. *Annals of Neurology*, **2003**, 54, 403-14	9.4	1206
259	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. *Annals of Neurology*, **2006**, 59, 459-66	9.4	785
258	Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. *Science* , **2001**, 293, 1164-6	33.3	732
257	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. *Annals of Neurology*, **2003**, 54, 93-101	9.4	691
256	Double-blind study of botulinum toxin in spasmodic torticollis. *Lancet, The*, **1986**, 2, 245-7	40	539
255	Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. *Lancet Neurology, The*, **2008**, 7, 400-8	24.1	450
254	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. *Annals of Neurology*, **2000**, 47, 493-503	9.4	443
253	Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. *Movement Disorders*, **2013**, 28, 811-3	7	433
252	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. *Movement Disorders*, **2017**, 32, 1264-1310	7	375
251	Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. *Brain*, **2004**, 127, 2747-54	11.2	307
250	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. *Progress in Neurobiology*, **2015**, 132, 96-168	10.9	282
249	Neural transplantation for the treatment of Parkinson's disease. *Lancet Neurology, The*, **2003**, 2, 437-45	24.1	278
248	Dopamine release in human ventral striatum and expectation of reward. *Behavioural Brain Research* , **2002**, 136, 359-63	3.4	275
247	Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. *Nature*, **1985**, 317, 246-8	50.4	270
246	DCTN1 mutations in Perry syndrome. *Nature Genetics*, **2009**, 41, 163-5	36.3	239
245	DNAJC13 mutations in Parkinson disease. *Human Molecular Genetics*, **2014**, 23, 1794-801	5.6	209

244	PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. *Brain*, **2005**, 128, 2777-85	11.2	208
243	Bilateral human fetal striatal transplantation in Huntington's disease. *Neurology*, **2002**, 58, 687-95	6.5	208
242	Effects of expectation on placebo-induced dopamine release in Parkinson disease. *Archives of General Psychiatry*, **2010**, 67, 857-65		207
241	Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. *JAMA Neurology*, **2015**, 72, 100-5	17.2	191
240	Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. *Brain*, **2009**, 132, 2970-9	11.2	185
239	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. *Annals of Neurology*, **2001**, 49, 298-303	9.4	179
238	Age-dependent decline of dopamine D1 receptors in human brain: a PET study. *Synapse*, **1998**, 30, 56-61	2.4	175
237	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. *Movement Disorders*, **2007**, 22, 2409-17	7	174
236	The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. *American Journal of Human Genetics*, **2004**, 74, 11-9	11	169
235	Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. *Annals of Neurology*, **2011**, 69, 803-10	9.4	168
234	The placebo effect in neurological disorders. *Lancet Neurology, The*, **2002**, 1, 85-91	24.1	142
233	Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. *Brain*, **2019**, 142, 512-525	11.2	142
232	Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. *Experimental Neurology*, **2003**, 184 Suppl 1, S68-79	5.7	133
231	The placebo effect in Parkinson's disease. *Trends in Neurosciences*, **2002**, 25, 302-6	13.3	123
230	Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. *Movement Disorders*, **2003**, 18, 157-62	7	118
229	The effects of exercise on cognition in Parkinson's disease: a systematic review. *Translational Neurodegeneration*, **2014**, 3, 5	10.3	114
228	Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). *Movement Disorders*, **2004**, 19, 622-9	7	112
227	Placebo mechanisms and reward circuitry: clues from Parkinson's disease. *Biological Psychiatry*, **2004**, 56, 67-71	7.9	107

226	Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. *Annals of Neurology*, **2007**, 62, 468-74	9.4	106
225	PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. *American Journal of Psychiatry*, **2002**, 159, 768-74	11.9	105
224	Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. *Lancet, The*, **2014**, 384, 532-44	40	104
223	SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. *Neurology* , **2002**, 59, 1625-7	6.5	103
222	Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. *Brain*, **2011**, 134, 3290-8	11.2	102
221	Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. *Journal of Cerebral Blood Flow and Metabolism*, **2002**, 22, 232-9	7.3	101
220	Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. *Brain*, **2004**, 127, 888-99	11.2	98
219	Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. *Neurology*, **2008**, 71, 1790-5	6.5	95
218	PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. *Neurology*, **2009**, 72, 1211-6	6.5	92
217	Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. *Movement Disorders*, **2006**, 21, 1457-61	7	88
216	Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. *Current Medical Research and Opinion*, **2018**, 34, 2063-2073	2.5	82
215	Advances in imaging in Parkinson's disease. *Lancet Neurology, The*, **2011**, 10, 987-1001	24.1	82
214	Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. *Movement Disorders*, **2010** , 25, 2717-23	7	82
213	Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. *Parkinsonism and Related Disorders*, **2009**, 15, 300-6	3.6	78
212	Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. *Journal of Parkinson's Disease*, **2019**, 9, 301-313	5.3	75
211	Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. *Journal of Cerebral Blood Flow and Metabolism*, **2004**, 24, 869-76	7.3	73
210	PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. *American Journal of Psychiatry*, **2002**, 159, 1718-23	11.9	73
209	Pallidonigral TDP-43 pathology in Perry syndrome. *Parkinsonism and Related Disorders*, **2009**, 15, 281-6	3.6	72

208	Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide. *Brain Research*, **1990**, 534, 1-7	3.7	72
207	Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. *Brain*, **2006**, 129, 1050-8	11.2	71
206	Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. *Neurology*, **2012**, 78, 649-57	6.5	69
205	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. *Movement Disorders*, **2009**, 24, 336-43	7	68
204	Nigrostriatal dopamine system and motor lateralization. *Behavioural Brain Research*, **2000**, 112, 63-8	3.4	67
203	Understanding the placebo effect: contributions from neuroimaging. *Molecular Imaging and Biology* , **2007**, 9, 176-85	3.8	65
202	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. *Lancet Neurology, The*, **2017**, 16, 351-359	24.1	64
201	Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography. *Neurology*, **1998**, 50, 1028-32	6.5	64
200	Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. *Stroke*, **1985**, 16, 734-6	6.7	64
199	Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. *British Journal of Psychiatry*, **2010**, 196, 474-9	5.4	61
198	Functional imaging in Parkinson disease. *Neurology*, **2008**, 70, 1478-88	6.5	61
197	VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. *Synapse*, **2003**, 49, 20-8	2.4	61
196	Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. *Annals of Neurology*, **2008**, 63, 388-94	9.4	60
195	Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia. *Neurology*, **2006**, 66, 1588-90	6.5	58
194	The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats. *British Journal of Pharmacology*, **1988**, 94, 285-7	8.6	58
193	[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. *Brain*, **2003**, 126, 2648-55	11.2	57
192	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. *Movement Disorders*, **2017**, 32, 181-192	7	56
191	Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. *Journal of Neural Transmission*, **2000**, 107, 49-57	4.3	56

190	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. *Annals of Neurology*, **2017**, 81, 46-57	9.4	54
189	Phosphorylated □synuclein in Parkinson's disease: correlation depends on disease severity. *Acta Neuropathologica Communications*, **2015**, 3, 7	7.3	53
188	Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. *Brain Research*, **1991**, 565, 254-62	3.7	52
187	Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. *Neurobiology of Aging*, **2017**, 57, 248.e7-248.e12	5.6	51
186	Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists. *Psychopharmacology*, **1989**, 98, 372-9	4.7	51
185	Positron emission tomography after fetal transplantation in Huntington's disease. *Annals of Neurology*, **2005**, 58, 331-7	9.4	50
184	SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. *Neurogenetics*, **2014**, 15, 23-30	3	49
183	Neuroimaging in Parkinson's disease. *Neurotherapeutics*, **2011**, 8, 72-81	6.4	49
182	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. *Annals of Neurology*, **2001**, 49, 298-303	9.4	49
181	The biochemical bases for reward. Implications for the placebo effect. *Evaluation and the Health Professions*, **2002**, 25, 387-98	2.5	48
180	PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins. *Movement Disorders*, **2017**, 32, 1016-1024	7	46
179	Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. *Journal of Cerebral Blood Flow and Metabolism*, **2001**, 21, 1151-9	7.3	46
178	Unilateral pallidotomy for reduction of parkinsonian pain. *Journal of Neurosurgery*, **1999**, 91, 198-201	3.2	46
177	Localization of striatal and nigral tachykinin receptors in the rat. *Brain Research*, **1994**, 646, 13-8	3.7	46
176	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. *Parkinsonism and Related Disorders*, **2013**, 19, 869-77	3.6	45
175	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. *Neurology*, **2013**, 81, 1322-31	6.5	45
174	Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. *Pharmacology & Therapeutics*, **2013**, 140, 306-18	13.9	43
173	Visualizing vesicular dopamine dynamics in Parkinson's disease. *Synapse*, **2009**, 63, 713-6	2.4	42

172	Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. *Journal of Neurochemistry*, **2009**, 109, 85-92	6	42
171	Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. *Movement Disorders*, **2007**, 22, 359-65	7	42
170	Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease. *Movement Disorders*, **2019**, 34, 1891-1900	7	41
169	Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. *Neuroscience*, **2003**, 116, 307-14	3.9	41
168	Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. *Archives of Neurology*, **2004**, 61, 1920-5		41
167	Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy. *Brain Research*, **1989**, 495, 20-30	3.7	39
166	Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT. *Brain Research*, **1990**, 517, 111-6	3.7	39
165	DNAJC12 and dopa-responsive nonprogressive parkinsonism. *Annals of Neurology*, **2017**, 82, 640-646	9.4	38
164	Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal microsomes. *Prostaglandins*, **1977**, 14, 819-27		38
163	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. *Movement Disorders*, **2019**, 34, 1406-1422	7	37
162	Cerebrospinal fluid amyloid and tau in LRRK2 mutation carriers. *Neurology*, **2012**, 78, 55-61	6.5	37
161	Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET. *Parkinsonism and Related Disorders*, **2001**, 7, 305-309	3.6	37
160	Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. *Synapse*, **2010**, 64, 146-51	2.4	36
159	Pallidotomy for tardive dyskinesia. *Lancet, The*, **1997**, 349, 777-8	40	36
158	Cerebral metabolism of glucose in benign hereditary chorea. *Movement Disorders*, **1986**, 1, 33-44	7	36
157	Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra. *Psychopharmacology*, **1987**, 93, 336-42	4.7	36
156	Glucose utilization: still in the synapse. *Nature Neuroscience*, **2017**, 20, 382-384	25.5	35
155	The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. *Lancet Neurology, The*, **2018**, 17, 309-316	24.1	35

154	Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. *PLoS ONE*, **2012**, 7, e43099	3.7	35
153	Positron emission tomography in premotor Parkinson's disease. *Parkinsonism and Related Disorders*, **2007**, 13 Suppl 3, S421-4	3.6	35
152	Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. *Molecular Brain Research*, **2005**, 134, 24-33		35
151	Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse. *Neuroscience Letters*, **1987**, 80, 321-6	3.3	33
150	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. *Journal of Parkinsonʼs Disease*, **2019**, 9, 31-61	5.3	33
149	DNAJC13 genetic variants in parkinsonism. *Movement Disorders*, **2015**, 30, 273-8	7	32
148	Neuroimaging in Parkinson's disease: from pathology to diagnosis. *Parkinsonism and Related Disorders*, **2012**, 18 Suppl 1, S55-9	3.6	32
147	Age and severity of nigrostriatal damage at onset of Parkinson's disease. *Synapse*, **2003**, 47, 152-8	2.4	32
146	DJ-1 and □YN in LRRK2 CSF do not correlate with striatal dopaminergic function. *Neurobiology of Aging*, **2012**, 33, 836.e5-7	5.6	31
145	Autosomal dominant dystonia-plus with cerebral calcifications. *Neurology*, **2006**, 67, 620-5	6.5	31
144	Rett syndrome: investigation of nine patients, including PET scan. *Canadian Journal of Neurological Sciences*, **2002**, 29, 345-57	1	31
143	Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. *Archives of Neurology*, **1995**, 52, 1160-3		31
142	The biochemical bases of the placebo effect. *Science and Engineering Ethics*, **2004**, 10, 143-50	3.1	30
141	Daytime somnolence in patients with Parkinson's disease. *Parkinsonism and Related Disorders*, **2001**, 7, 283-286	3.6	30
140	(+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism. *Lancet, The*, **1985**, 2, 1330-1	40	30
139	Is Axonal Degeneration a Key Early Event in Parkinson's Disease?. *Journal of Parkinsonʼs Disease*, **2016**, 6, 703-707	5.3	30
138	GDNF in treatment of Parkinson's disease: response to editorial. *Lancet Neurology, The*, **2006**, 5, 200-2	24.1	29
137	Etiology of Parkinson's disease. *Canadian Journal of Neurological Sciences*, **2003**, 30 Suppl 1, S10-8	1	29

136	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. *Journal of Parkinson's Disease*, **2020**, 10, 875-891	5.3	28
135	Nemaline myopathy with associated cardiomyopathy. Report of clinical and detailed autopsy findings. *Archives of Neurology*, **1985**, 42, 1084-6		28
134	Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. *Journal of Parkinson's Disease*, **2014**, 4, 483-98	5.3	27
133	Response to heat pain stimulation in idiopathic Parkinson's disease. *Pain Medicine*, **2010**, 11, 834-40	2.8	27
132	Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. *Parkinsonism and Related Disorders*, **2009**, 15, 539-41	3.6	26
131	Glucose use correlations: a matter of inference. *Journal of Cerebral Blood Flow and Metabolism*, **1986**, 6, 511-2	7.3	26
130	COVID-19 and selective vulnerability to Parkinson's disease. *Lancet Neurology, The*, **2020**, 19, 719	24.1	26
129	Neuroimaging in the early diagnosis of neurodegenerative disease. *Translational Neurodegeneration*, **2012**, 1, 5	10.3	25
128	A family with Parkinsonism, essential tremor, restless legs syndrome, and depression. *Neurology*, **2011**, 76, 1623-30	6.5	25
127	A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. *NeuroReport*, **1997**, 8, 669-72	1.7	25
126	Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. *Neuroscience*, **2000**, 101, 629-35	3.3	24
125	Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). *Parkinsonism and Related Disorders*, **2001**, 7, 81-88	3.6	24
124	DCTN1 p.K56R in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2016**, 28, 56-61	3.6	24
123	The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling. *PLoS ONE*, **2013**, 8, e76595	3.7	23
122	Clustering of Parkinson disease: shared cause or coincidence?. *Archives of Neurology*, **2004**, 61, 1057-60		23
121	Environmental exposures in elderly Canadians with Parkinson's disease. *Canadian Journal of Neurological Sciences*, **1995**, 22, 232-4	1	23
120	Etiology of Parkinson's disease. *Canadian Journal of Neurological Sciences*, **1999**, 26 Suppl 2, S5-12	1	22
119	Gender differences in Parkinson's disease depression. *Parkinsonism and Related Disorders*, **2017**, 36, 93-97	3.6	21

118	Neuroimaging: current role in detecting pre-motor Parkinson's disease. *Movement Disorders*, **2012**, 27, 634-43	7	21
117	In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 59-66	7.3	21
116	Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. *Neuroscience*, **2002**, 112, 851-9	3.9	21
115	Effects of neurotensin in a rodent model of tardive dyskinesia. *Neuropharmacology*, **1995**, 34, 457-62	5.5	21
114	Tremor induced by thalamic deep brain stimulation in patients with complex regional facial pain. *Movement Disorders*, **2004**, 19, 933-6	7	20
113	Willing oneself better on placebo--effective in its own right. *Lancet, The*, **2004**, 364, 227-8	40	20
112	Parkinson's disease: imaging update. *Current Opinion in Neurology*, **2002**, 15, 477-82	7.1	20
111	Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going. *Movement Disorders*, **2018**, 33, 1213-1227	7	20
110	Optimizing diagnosis in Parkinson's disease: Radionuclide imaging. *Parkinsonism and Related Disorders*, **2016**, 22 Suppl 1, S47-51	3.6	18
109	Biomarkers for trials of neuroprotection in Parkinson's disease. *Movement Disorders*, **2013**, 28, 71-85	7	18
108	Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity. *Synapse*, **2000**, 37, 171-8	2.4	18
107	Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study. *Movement Disorders*, **2018**, 33, 1945-1950	7	18
106	Investigation of serotonergic Parkinson's disease-related covariance pattern using [C]-DASB/PET. *NeuroImage: Clinical*, **2018**, 19, 652-660	5.3	18
105	The placebo response as a reward mechanism. *Seminars in Pain Medicine*, **2005**, 3, 37-42		17
104	Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. *Synapse*, **1996**, 24, 256-61	2.4	17
103	The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. *Movement Disorders*, **1993**, 8, 445-52	7	17
102	Regression model for predicting dissociations of regional cerebral glucose metabolism in individuals at risk for Huntington's disease. *Journal of Cerebral Blood Flow and Metabolism*, **1986**, 6, 756-62	7.3	17
101	Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. *Progress in Brain Research*, **2010**, 184, 177-92	2.9	16

100	Functional imaging studies of non-motoric manifestations of Parkinson's Disease. *Parkinsonism and Related Disorders*, **2009**, 15 Suppl 3, S13-6	3.6	16
99	The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation. *Psychopharmacology*, **1988**, 95, 502-6	4.7	16
98	Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. *Movement Disorders*, **2014**, 29, 1684-7	7	15
97	Novel spatial analysis method for PET images using 3D moment invariants: applications to Parkinson's disease. *NeuroImage*, **2013**, 68, 11-21	7.9	15
96	Gene therapy for Parkinson's disease: a step closer?. *Lancet, The*, **2014**, 383, 1107-9	40	15
95	Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders. *Journal of Psychopharmacology*, **1989**, 3, 99-120	4.6	15
94	Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat. *Brain Research*, **1991**, 558, 289-95	3.7	15
93	The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. *Translational Neurodegeneration*, **2017**, 6, 4	10.3	14
92	Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations. *NeuroImage: Clinical*, **2019**, 23, 101856	5.3	14
91	Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. *EJNMMI Research*, **2013**, 3, 69	3.6	14
90	Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. *Neuroscience*, **2003**, 119, 547-55	3.9	14
89	Dopamine D1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone. *European Journal of Pharmacology*, **1994**, 259, 301-3	5.3	14
88	Win-Concurrent Sensory Cues Can Promote Riskier Choice. *Journal of Neuroscience*, **2018**, 38, 10362-10370	6	14
87	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. *Movement Disorders Clinical Practice*, **2014**, 1, 67-69	2.2	13
86	Gene therapy for Parkinson's disease: early data. *Lancet, The*, **2007**, 369, 2056-8	40	13
85	Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. *Brain Research*, **1995**, 700, 115-20	3.7	13
84	Effects of ageing on tachykinin function in the basal ganglia. *Brain Research*, **1993**, 632, 21-8	3.7	13
83	In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. *Movement Disorders*, **2014**, 29, 1197-201	7	12

82	Imaging striatal dopaminergic function in phospholipase A2 group VI-related parkinsonism. *Movement Disorders*, **2012**, 27, 1698-9	7	12
81	Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies. *Movement Disorders*, **2006**, 21, 970-5	7	12
80	Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. *Neuroscience*, **2000**, 98, 61-7	3.9	12
79	A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. *Movement Disorders*, **2016**, 31, 405-9	7	12
78	Imaging neural correlates of mild cognitive impairment in Parkinson's disease. *Lancet Neurology, The*, **2012**, 11, 653-5	24.1	11
77	Potential therapeutic targets for Parkinson's disease. *Expert Opinion on Therapeutic Targets*, **2008**, 12, 425-36	6.4	11
76	[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism. *Movement Disorders*, **2002**, 17, 789-94	7	11
75	Controlling for cerebral atrophy in positron emission tomography data. *Journal of Cerebral Blood Flow and Metabolism*, **1987**, 7, 510-2	7.3	11
74	Movement disorders. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2016**, 136, 957-69	3	10
73	Is there seasonal variation in risk of Parkinson's disease?. *Movement Disorders*, **2007**, 22, 1097-101	7	10
72	Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats. *Neuroscience*, **2002**, 112, 261-6	3.9	10
71	Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). *Current Opinion in Neurology*, **1998**, 11, 327-33	7.1	10
70	Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review. *JAMA Neurology*, **2021**, 78, 1262-1272	17.2	10
69	Dyskinesias and levodopa therapy: why wait?. *Journal of Neural Transmission*, **2018**, 125, 1119-1130	4.3	9
68	The role of biomarkers and imaging in Parkinson's disease. *Expert Review of Neurotherapeutics*, **2016**, 16, 187-203	4.3	9
67	Central pharmacokinetics of levodopa: Lessons from imaging studies. *Movement Disorders*, **2015**, 30, 73-9	7	8
66	Developments in neuroimaging: positron emission tomography. *Parkinsonism and Related Disorders*, **2014**, 20 Suppl 1, S180-3	3.6	8
65	Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude. *Neuropsychologia*, **2013**, 51, 2679-89	3.2	8

64	Positron emission tomography of dopamine pathways in familial Parkinsonian syndromes. *Parkinsonism and Related Disorders*, **2001**, 8, 51-6	3.6	8
63	Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. *European Journal of Pharmacology*, **1996**, 298, 7-15	5.3	8
62	Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. *PLoS ONE*, **2018**, 13, e0206607	3.7	8
61	Reversible Parkinsonism and Rapidly Progressive Dementia Due to Dural Arteriovenous Fistula: Case Series and Literature Review. *Movement Disorders Clinical Practice*, **2017**, 4, 607-611	2.2	7
60	Milestones in neuroimaging. *Movement Disorders*, **2011**, 26, 868-978	7	7
59	Prevention and Management of Late Stage Complications in Parkinson Disease. *Canadian Journal of Neurological Sciences*, **1992**, 19, 113-116	1	7
58	Ethical and Clinical Considerations at the Intersection of Functional Neuroimaging and Disorders of Consciousness. *Cambridge Quarterly of Healthcare Ethics*, **2016**, 25, 613-22	0.9	7
57	A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study. *Parkinsonism and Related Disorders*, **2014**, 20, 1129-34	3.6	6
56	Imaging in multiple system atrophy. *Neurology and Clinical Neuroscience*, **2014**, 2, 178-187	0.3	6
55	Canadian perspectives on the clinical actionability of neuroimaging in disorders of consciousness. *Canadian Journal of Neurological Sciences*, **2015**, 42, 96-105	1	6
54	Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?. *Nature Clinical Practice Neurology*, **2009**, 5, 10-1		6
53	Dementia in movement disorders. *Canadian Journal of Neurological Sciences*, **1986**, 13, 546-58	1	6
52	Optical coherence tomography of patients with Parkinson's disease and progressive supranuclear palsy. *Clinical Neurology and Neurosurgery*, **2020**, 189, 105635	2	6
51	Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. *Movement Disorders*, **2021**, 36, 389-397	7	6
50	PBB3 binding in a patient with corticobasal syndrome. *Movement Disorders*, **2018**, 33, 1359-1360	7	5
49	Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum. *Neuroscience*, **1997**, 76, 1173-85	3.9	5
48	Treatment for the progression of Parkinson's disease. *Lancet Neurology, The*, **2005**, 4, 206	24.1	5
47	Differential diagnosis of parkinsonism. *Canadian Journal of Neurological Sciences*, **1999**, 26 Suppl 2, S1-4	1	5

46	Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies. *Movement Disorders*, **2021**, 36, 1781-1791	7	5
45	Salivary gland biopsy for diagnosis of Parkinson's disease?. *Lancet Neurology, The*, **2016**, 15, 654-656	24.1	5
44	Challenges and unfulfilled promises in Parkinson's disease. *Lancet Neurology, The*, **2017**, 16, 866-867	24.1	4
43	The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat. *Neuropharmacology*, **1997**, 36, 93-9	5.5	4
42	The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: evidence for a novel CCK receptor subtype?. *Neuropharmacology*, **1997**, 36, 1679-88	5.5	4
41	Effect of age on caudate dopaminergic function in idiopathic Parkinsonism. *Parkinsonism and Related Disorders*, **1998**, 4, 1-5	3.6	4
40	Agonizing over dopaminergic replacement therapy--lessons from animal models of Parkinson's disease. *Experimental Neurology*, **2003**, 183, 1-3	5.7	4
39	Effects of ethanol in a putative rodent model of tardive dyskinesia. *Pharmacology Biochemistry and Behavior*, **1996**, 54, 541-6	3.9	4
38	Neuroleptic-induced chewing movements in the rat are suppressed by peripherally but not centrally administered CCK and abolished by bilateral subdiaphragmatic vagotomy. *Neuropharmacology*, **1993**, 32, 555-60	5.5	4
37	PET Molecular Imaging in Familial Parkinson's Disease. *International Review of Neurobiology*, **2018**, 142, 177-223	4.4	4
36	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease **2000**, 47, 493		4
35	. *IEEE Transactions on Nuclear Science*, **2004**, 51, 205-211	1.7	3
34	Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. *Canadian Journal of Neurological Sciences*, **2005**, 32, 277-86	1	3
33	Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade. *Parkinsonism and Related Disorders*, **1996**, 2, 167-75	3.6	3
32	Neuroimaging of Sleep and Sleep Disorders **2013**,		3
31	Imaging in Parkinson's disease: time to look below the neck. *Brain*, **2015**, 138, 512-4	11.2	2
30	Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?. *Neurology*, **2016**, 86, 228	6.5	2
29	Neurology in Canada: history of the Canadian Neurological Society. *Neurology*, **2013**, 80, 406-8	6.5	2

28	Movement disorders: new insights into Parkinson's disease. *Lancet Neurology, The*, **2011**, 10, 5-7	24.1	2
27	Joubert syndrome surviving to adulthood associated with a progressive movement disorder. *Movement Disorders*, **2007**, 22, 262-5	7	2
26	Pharmacodynamic modeling of oral levodopa in Parkinson's disease. *Annals of Neurology*, **2001**, 50, 687-8	9.4	2
25	Positron Emission Tomography in Parkinson Disease **2005**, 25-35		2
24	Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US. *Npj Parkinson's Disease*, **2021**, 7, 21	9.7	2
23	Occult central pontine myelinolysis post liver transplant: A consequence of pre-transplant hyponatremia. *Annals of Hepatology*, **2019**, 18, 651-654	3.1	1
22	Liquid Xenon Detectors for Positron Emission Tomography. *Journal of Physics: Conference Series*, **2011**, 312, 062006	0.3	1
21	A brain network response to sham surgery. *Journal of Clinical Investigation*, **2014**, 124, 3285-8	15.9	1
20	Movement Disorders Journal: Yesterday, Today, Tomorrow, and Always. *Movement Disorders*, **2019**, 34, 1814-1816	7	1
19	Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner. *Parkinsonism and Related Disorders*, **2019**, 66, 189-194	3.6	0
18	Deception and the ethics of placebo. *International Review of Neurobiology*, **2020**, 153, 147-163	4.4	0
17	Novel data-driven, equation-free method captures spatio-temporal patterns of neurodegeneration in Parkinson's disease: Application of dynamic mode decomposition to PET. *NeuroImage: Clinical*, **2020**, 25, 102150	5.3	0
16	Immunotherapy for Parkinson's disease: stay tuned. *Lancet Neurology, The*, **2020**, 19, 561-562	24.1	
15	Conclusions. *Movement Disorders*, **2018**, 33, 701	7	
14	Neuroimaging of Parkinson disease and multiple system atrophy in patients with sleep disturbance305-315		
13	Imaging of Dopamine and Serotonin Receptors and Transporters **2014**, 241-264		
12	Functional Imaging Studies in Parkinson's Disease: The Non-Dopaminergic Systems **2011**, 105-110		
11	Neuroimaging of Parkinson's disease361-370		

10	Parkin and Parkinson's disease: differentiated by non-dopaminergic dysfunction?. *Experimental Neurology*, **2010**, 225, 48-50	5.7
9	On the Use of Clusters to Determine Environmental Influence on Disease:Reply. *Archives of Neurology*, **2005**, 62, 331	
8	Antisense strategies for the treatment of neurological disease. *Expert Opinion on Therapeutic Patents*, **2001**, 11, 547-562	6.8
7	Cortical morphology predicts placebo response in multiple sclerosis.. *Scientific Reports*, **2022**, 12, 732	4.9
6	LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism **2008**, 75-89	
5	Insights into LRRK2-Mutation Related PD from PET Imaging Studies **2014**, 123-124	
4	Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis **2014**, 161	
3	Raul de la Fuente-Fernandez, February 22, 1959-May 11, 2016. *Movement Disorders*, **2016**, 31, 1144-5	7
2	Reply to letter to the editor: Is there anything more to learn from SWEDD?. *Movement Disorders*, **2016**, 31, 1426-8	7
1	Operationalizing Neuroimaging for Disorders of Consciousness in the Canadian Context. *Canadian Journal of Neurological Sciences*, **2018**, 45, 633-635	1